
Mark Nathan Wolf
About Mark Nathan Wolf
Data last updated:
Mark Nathan Wolf is a Director at Contract Pharmacal Corporation India Private Limited (since 2013). The company operates in Pharma. Contract Pharmacal Corporation India Private Limited reported revenue of ₹10.47 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 24 Jun 2013 | 2013 | ₹10.47 Cr (FY 2024) | Active |
Board colleagues of Mark Nathan Wolf
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ketan Babulal Dalki | 09572318 | Contract Pharmacal Corporation India Private Limited | Additional Director |
| Matthew David Wolf | 06536763 | Contract Pharmacal Corporation India Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Mark Nathan Wolf
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mark Nathan Wolf
Mark Nathan Wolf currently holds 1 directorship: Contract Pharmacal Corporation India Private Limited (Director, since 24 Jun 2013, revenue ₹10.47 Cr (FY 2024)).
Mark Nathan Wolf was first appointed on 24 Jun 2013 as Director at Contract Pharmacal Corporation India Private Limited.
The current boards of Mark Nathan Wolf's companies include Ketan Babulal Dalki (Contract Pharmacal Corporation India Private Limited), Matthew David Wolf (Contract Pharmacal Corporation India Private Limited).